NASDAQ:CTMX - CytomX Therapeutics, Inc.
$11.79
 $-0.03
-0.25%
4:00PM EDT
2019-07-15
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  CTMX     avg for
industry  
  avg for
sector  
42 stocks weight:  54. 81   114. 77   204. 78  
42 stocks rank:  2. 20 K 1. 44 K 810. 33  
# analyst opinions:  10. 00   13. 59   13. 86  
mean recommendation:  1. 90   2. 12   2. 04  

quick ratio:  4. 12   5. 48   1. 89  
current ratio:  4. 21   5. 85   2. 40  

target price low:  12. 00   82. 72   115. 11  
target price avg:  20. 80   104. 42   138. 02  
target price high:  30. 00   130. 64   159. 47  
1-yr high:  26. 41   110. 27   142. 72  
last close:  11. 82   85. 12   126. 54  
50-day avg:  10. 71   86. 06   122. 35  
200-day avg:  13. 37   88. 76   121. 75  
1-yr low:  9. 35   69. 26   100. 63  
volume:  191. 58 K 3. 51 M 5. 53 M
50-day avg volume:  384. 30 K 3. 21 M 4. 22 M
200-day avg volume:  442. 44 K 3. 04 M 4. 75 M

1-day return:  0. 25 % -0. 30 % -1. 01 %
this week return:  5. 25 % -2. 16 % -1. 35 %
12-wk return:  18. 32 % 3. 34 % 8. 69 %
52-wk return:  -51. 74 % -1. 76 % 12. 22 %

enterprise value (EV):  186. 66 M 46. 50 B 123. 99 B
market cap:  541. 76 M 40. 77 B 109. 11 B
EBITDA:  -76. 68 M 4. 33 B 8. 19 B
enterprise multiple (EV/EBITDA):  -2. 43   5. 45   12. 05  
enterprise/revenue (EV/R):  2. 50   50. 46   9. 50  
total revenue:  74. 80 M 10. 21 B 40. 60 B
total debt:  29. 55 M 11. 27 B 17. 58 B
debt/equity:  24. 11   57. 36   120. 25  
net income (common):  -83. 23 M 2. 13 B 4. 27 B

shares outstanding:  0. 00   551. 08 M 1. 24 B
shares:  41. 08 M 559. 41 M 1. 22 B
shares short:  1. 67 M 11. 15 M 11. 94 M
shares short prior month:  1. 90 M 9. 31 M 11. 96 M
short ratio:  4. 92   5. 72   3. 43  
short % of float:  3. 75 % 6. 40 % 2. 65 %
total cash/share:  8. 75   11. 00   9. 23  
total cash:  396. 60 M 6. 03 B 6. 01 B
free cash flow:  -12. 58 M 3. 02 B 4. 96 B
operating cash flow:  -99. 94 M 3. 92 B 5. 99 B

book value:  2. 71   13. 02   27. 49  
price/book:  4. 36   4. 21   8. 80  
gross profits:  59. 50 M 7. 67 B 36. 29 B
operating margins:  -105. 36 % -380. 20 % -38. 44 %
EBITDA margins:  -102. 52 % 13. 59 % 23. 24 %
profit margins:  -111. 27 % 10. 94 % 14. 00 %
gross margins:  100. 00 % 36. 11 % 55. 16 %

1-yr max volatility:  31. 27 % --- ---
1-yr mean volatility:  2. 96 % 1. 50 % 1. 08 %

1-yr EPS:  -1. 92   2. 12   4. 26  
forward EPS:  -2. 82   3. 47   7. 14  
P/E:  -6. 15   2. 15   33. 17  
forward P/E:  -4. 18   -4. 03   17. 60  
PE/G:  -0. 06   0. 54   0. 34  
growth:  107. 90 % 263. 03 % 78. 34 %
earnings high:  -0. 34   0. 91   1. 70  
earnings avg:  -0. 57   0. 71   1. 58  
earnings low:  -0. 81   0. 48   1. 46  
revenue high:  31. 25 M 2. 64 B 11. 26 B
revenue avg:  16. 58 M 2. 58 B 11. 09 B
revenue low:  8. 00 M 2. 54 B 10. 90 B
return on assets:  -12. 00 % -2. 31 % 5. 31 %
return on equity:  -96. 66 % -82. 48 % 135. 30 %
revenue growth:  107. 90 % 262. 60 % 72. 94 %
revenue/share:  1. 73   12. 77   61. 38  

beta (1yr vs S&P500):  1. 99   1. 26   0. 91  
sharpe (1yr):  -0. 61   0. 07   0. 77  

held % insiders:  2. 50 % 6. 08 % 3. 31 %
held % institutions:  86. 29 % 78. 36 % 69. 61 %

Research more with google or yahoo!
the data below are updated and re-published at 8pm EDT after each trading day

2019-07-14 : CTMX
.    115.273 =       115.273 :: --> INITIAL WEIGHT <--
.    - 1.923 =        113.35 :: earnings per-share addition
.                               --> FUNDAMENTALS <--
.    x 2.114 =       239.572 :: P/E factor
.    x 2.047 =       490.379 :: PE/G factor
.    x 1.593 =       781.237 :: beta factor
.    x 0.858 =       670.341 :: sharpe factor
.    x 2.719 =      1822.786 :: current ratio factor
.    x 1.149 =      2094.466 :: quick ratio factor
.    x 1.097 =      2297.479 :: short ratio factor
.    x 2.127 =      4885.975 :: revenue growth factor
.    x 1.049 =      5127.561 :: EV/R factor
.    x 1.054 =      5402.405 :: price-to-book factor
.    x 2.531 =     13674.746 :: debt-to-revenue factor
.    x 1.192 =      16297.32 :: debt-to-equity factor
.                               --> PERFORMANCE <--
.    x 2.114 =      34452.28 :: sector+industry 1-year gains factor
.    x 1.033 =     35602.918 :: industry 12-weeks return factor
.    x 1.305 =     46471.552 :: industry 2-weeks return factor
.     x 0.88 =     40906.991 :: company one-year gains+dividend factor
.     x 3.68 =    150555.421 :: company 13 weeks' performance factor
.    x 1.422 =     214139.25 :: 5-day avg > 50-day avg
.    x 0.977 =    209119.857 :: "drift" penalty 2 days ago
.    x 0.977 =     204264.41 :: "drift" penalty 4 days ago
.    / 2.046 =     99815.685 :: overall "drift" factor
.    x 0.795 =     79402.812 :: largest single-day jump factor
.    x 0.187 =     14813.957 :: low price factor
.    x 1.333 =     19749.795 :: notable returns + performance factor
.    x 2.906 =     57387.605 :: performance vs s&p500 factor
.    x 3.138 =    180076.741 :: inverse volume-to-price factor
.                               --> PROJECTIONS <--
.    x 0.719 =    129460.977 :: forward EPS factor
.    x 0.898 =    116238.027 :: forward P/E factor
.    x 1.182 =    137445.522 :: industry recommendation factor
.    x 2.408 =    330964.986 :: company recommendation factor
.    x 1.008 =     333496.32 :: factor historical industry gain for week 28
.    x 1.153 =    384557.581 :: target low factor
.    x 1.291 =    496287.517 :: target mean factor
.    x 1.052 =     522138.13 :: target high factor
.   x 11.064 =   5776827.529 :: spline projection factor
.                               --> FINAL ADJUSTMENTS <--
.  quad root =        49.026 :: reduced for readability
.    + 5.785 =         54.81 :: add/subtract for investor sentiment
.                               --> FINAL WEIGHT <--
.                      54.81 :: FINAL WEIGHT for NASDAQ:CTMX


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org